Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Somatostatin levels in the basal ganglia are elevated in Huntington's disease. A controlled therapeutic trial of the somatostatin-depleting agent, cysteamine, was therefore conducted in five patients, including one with the rigid-akinetic form. Maximum tolerated dosage for 2 weeks produced no consistent change in extrapyramidal or dementia scores. Somatostatin concentrations were not significantly altered in plasma or CSF. Growth hormone levels, on the other hand, more than doubled, suggesting a functionally significant decrease in central somatostatin levels.
 ...
PMID:Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. 287 27

The effect of carbamazepine treatment on CSF-somatostatin-like immunoreactivity (SLI) in patients suffering from temporal lobe epilepsy was investigated. A baseline lumbar puncture was performed on 12 patients and 10 normal volunteers. A second tap was repeated only in patients when they were on peak of carbamazepine concentration for 10 days. Levels of CSF-SLI were measured by RIA. No significant differences were found in CSF-SLI basal concentrations between epileptics and controls, whereas a significant decrease (p less than .0002 Duncan's multiple range test) of CSF peptide levels occurred in 9 of 12 patients under medication. Although the neural mechanism through which carbamazepine lowers CSF-SLI is still unknown, the results of the present study suggest that the reported effect might be part of the apparatus by which carbamazepine exerts its anticonvulsant action.
 ...
PMID:Carbamazepine lowering effect on CSF somatostatin-like immunoreactivity in temporal lobe epileptics. 287 37

Somatostatin-like immunoreactivity in Alzheimer CSF was significantly lower than in that from age-matched controls. The degree of reduction correlated with indices of intellectual impairment and decline in cortical glucose utilization as determined by PET. There was a close association between reduction in CSF somatostatin and glucose hypometabolism in the parietal lobe. In postmortem cortical tissue from Alzheimer patients, somatostatin levels were lower in posterior parietal but not in anterior frontal cortex. Loss of somatostatin-containing neurons, especially in the parietal association cortex, may be a critical determinant for Alzheimer dementia.
 ...
PMID:Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. 287 58

CSF neurotransmitter markers may reflect neurochemical alterations in Alzheimer's disease (AD). The best studied neurochemical deficit in AD is that of acetylcholine. Both acetylcholinesterase and butyrylcholinesterase activity have been reported to be reduced in some but not all studies of AD CSF. Studies of monoamine metabolites have also been controversial but most authors have found reduced concentrations of CSF HVA, lesser reductions in HIAA and no change in MHPG. CSF GABA concentrations have been found to be reduced in AD. Studies of CSF neuropeptides in AD have shown reduced concentrations of somatostatin and vasopressin, normal concentrations of vasoactive intestinal polypeptide and either normal or decreased concentrations of beta-endorphin and corticotropin releasing factor. Although no individual CSF neurochemical markers are specific for AD it may be possible to develop a profile of several neurochemical markers which will have enhanced specificity.
 ...
PMID:CSF neurotransmitter markers in Alzheimer's disease. 287 17

Somatostatin is a neuropeptide that in several experimental models of epilepsy has been suggested to modulate epileptic activity. The purpose of the present study was to investigate the role of somatostatin in seizure phenomena. We measured the somatostatin-like immunoreactivity (SLI) by radioimmunoassay of the cisternal CSF of rats. A polyethylene cannula had before-hand been inserted into the cisterna magna. Thereafter seizures were induced by pentylenetetrazol (PTZ). The nonconvulsive group of rats received a single subconvulsive dose of PTZ (30 mg/kg, i.p.). This group of rats exhibited only clonic jerks but not generalized clonic-tonic convulsion (GC). The CSF samples were taken 2 and 10 minutes after the jerks began. The convulsive group of rats received a single convulsive dose of PTZ (50 mg/kg, i.p.), and each of those animals had GC. From those rats the CSF samples were collected 5, 30, and 60 minutes and 4 and 24 h after the GC began. The values were compared with the SLI levels in controls, from which CSF was collected 10 minutes after injection of 0.9% NaCl. In the convulsion group the SLI levels increased 241% (p less than 0.01) five minutes after GC and returned to control level in 30 minutes. In the nonconvulsion group, where the rats expressed only jerks but not GC, SLI levels remained constant. These data suggest that somatostatin is released into CSF after the generalized clonic-tonic phase of the PTZ-induced convulsion.
 ...
PMID:Effect of pentylenetetrazol-induced convulsions on somatostatin-like immunoreactivity in rat cerebrospinal fluid. 288 40

CSF and venous blood were sampled hourly during 24 hours in 6 control subjects and in 12 patients with MS, 5 of whom were in stable phase and 7 in relapse. CSF somatostatin immunoreactivity was 166 +/- 5.3 (SFM) pg/ml in controls at noon and rose around midnight to 208 +/- 3.8 pg/ml, then decreased to basal levels at about 5 hours and exhibited another small peak 3 hours later. Almost identical patterns were found in patients with MS during stable phase. During relapse, CSF somatostatin was reduced to 99 +/- 9.2 pg/ml and showed no variation from this value. CSF albumin was similar in the three groups and exhibited no fluctuations. Diurnal patterns of serum growth hormone were similar and unrelated to the oscillations in CSF somatostatin, indicating that hypothalamic release was insignificant in the overall production and in variations. The observation that the CNS releases somatostatin at lower levels during relapse in MS and that these do not oscillate may suggest that the constant low contents represent passive spillover from somatostatin-containing neurons, while the undulating levels above them are representative of active, yet unknown neurophysiologic (eg, neurotransmitter) functions which become reversibly extinct in relapse.
 ...
PMID:CSF somatostatin in multiple sclerosis: reversible loss of diurnal oscillation in relapses. 288 94

The anticonvulsant action of the new anticonvulsant drug gamma-vinyl-GABA (GVG) is obviously mediated by elevation of the concentration of GABA in the brain. The effect of GVG administration on other transmitter systems is not fully known in humans. We studied the possible interactions of GVG administration with peptidergic systems. Included in this study were 67 patients with complex partial epilepsy (CPS). The first CSF sample was taken before GVG administration. The second CSF sample was taken after 3 months of GVG treatment (3 g/day). Thereafter half of the responders (50% decrease in seizure frequency or clear improvement in global performance) received 3 g/day and the other half received 1.5 g/day for the next three months, after which the third CSF sample was taken. Somatostatin (SLI), beta-endorphin (beta-EP), and prolactin (PROL) levels in CSF were measured by radioimmunoassay. Total GABA (tGABA) and GVG levels in CSF were measured by high performance liquid chromatography. After 3 months of GVG treatment there was a slight increase in the beta-EP (p = 0.027, Student's paired t-test), which was not found after 6 months of GVG administration. Both SLI and PROL were stable during the study. Peptide levels were not connected to the clinical response to GVG, GVG dosage, or to tGABA levels in the CSF. In conclusion, the elevation of GABA levels in the brain during GVG treatment apparently does not induce long-term interactions with the peptidergic systems studied.
 ...
PMID:Somatostatin, beta-endorphin, and prolactin levels in human cerebrospinal fluid during the gamma-vinyl-GABA treatment of patients with complex partial epilepsy. 288 76

It is currently believed that Parkinson disease (PD) is due to a degenerative process that independently damages multiple areas of the central and peripheral nervous system. Loss of nigrostriatal dopamine is now widely recognized as being directly related to the motor symptoms in Parkinson's disease. Parkinsonian patients also exhibit symptoms and signs suggestive of hypothalamic dysfunction (e.g. dysautonomia, impaired heat tolerance). The latter clinical features are supported by pathological, biochemical and endocrinological findings. Lewy body formation has been demonstrated in every nucleus of the hypothalamus, specifically the tuberomamillary and posterior hypothalamic. Preferential involvement of the hypothalamus was also noted in patients after post-encephalitic parkinsonism. Loss of dopamine (30-40%) in the hypothalamus of affected patients has been shown in recent studies, and is compatible with the reported abnormalities of growth hormone release in response to L-dopa administration, elevated plasma levels of MSH, and reduced CSF levels of somatostatin and beta-endorphins in these patients. Deranged immunological mechanisms have been found in PD patients including the presence of autoantibodies against sympathetic ganglia neurons, adrenal medulla and caudate nucleus. On the evidence of on pathological studies demonstrating the early vulnerability of the hypothalamus in aging and PD, and the known role of the hypothalamus in immune modulation, we expect that it will be shown that primary damage of the hypothalamus leads to subsequent secondary degeneration of structures receiving direct projections from the hypothalamus. Within this framework, the dopaminergic systems may be damaged, since striatal dopamine synthesis and receptor sensitivity have been shown to be regulated by ACTH and alpha-MSH through direct arcuate nucleus-striatal projections.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The hypothalamus in Parkinson disease. 288 37

Levels of vasopressin, somatostatin, neurotensin, vasoactive intestinal peptide, corticotrophin-releasing factor and adrenocorticotrophin in CSF were determined in lithium-treated and unmedicated euthymic bipolar patients and controls, in a search for a trait marker in affective disorder. No group differences in levels of these peptides were found. Highly significant positive correlations were found among these peptides (with the exception of neurotensin), suggesting that their presence in CSF is functionally significant, as opposed to the result of random diffusion from the interstitial space of the brain.
 ...
PMID:CSF neuropeptides in euthymic bipolar patients and controls. 288 3

Several neuropsychiatric illnesses, including depression and Alzheimer's disease, are reported to be characterized by hypercortisolemia and by reduced levels of cerebrospinal fluid somatostatin-like immunoreactivity (CSF-SLI). To investigate a possible causal linkage between these abnormalities we administered prednisone, 80 mg orally per day for 5 days, to 9 healthy volunteers. We observed significant prednisone-induced reductions in CSF-SLI. Moreover, the magnitude of these reductions was inversely related to the magnitude of prednisone-induced reductions in plasma ACTH levels, suggesting a functional interaction between circulating corticosteroids, central somatostatin and pituitary ACTH release.
 ...
PMID:Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness. 288 25


<< Previous 1 2 3 4 5 6 7 8 9 Next >>